Glycosylated fibronectin in preeclampsia: a systematic review and meta-analysis.

ABSTRACT:

Background

Preeclampsia (PE) is a complex multisystem disease, and its timely diagnosis and treatment impact the health of patients and perinatal infants. Studies have reported elevated levels of maternal serum glycosylated fibronectin (GlyFn) in patients with PE compared with pregnant women without PE (controls), suggesting its potential as a novel biomarker for screening and diagnosing PE. Therefore, this study aims to evaluate maternal serum GlyFn levels and their diagnostic accuracy in PE.

Methods

A systematic literature search was conducted using PubMed, EMBASE, Web of Science, and the Cochrane Library up to January 15, 2024. The Newcastle-Ottawa Quality Assessment Scale and the Quality Assessment of Diagnostic Accuracy Studies-2 tool were used to evaluate study quality

SUBMITTER: Liao L 

PROVIDER: S-EPMC11871604 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature